Skip to content

Trending News

What Just Happened
4 years agoOptimizeRx Announces Agreement with a Top Pharmaceutical Manufacturer to Use its Evidence-Based Physician Engagement to Solve Lapse in Medical Coverage Barrier for Patients – Stockhouse 4 years agoOM1 Launches Multiple Sclerosis Registry with More than 20000 Patients Prospectively Followed with Deep Clinical Data – Markets Insider 4 years agoReal-World Evidence And Its Use In Advertising Of Medicinal Products In The EU And US – Media, Telecoms, IT, Entertainment – Worldwide – Mondaq News Alerts 4 years agoNational Evaluation System for health Technology Coordinating Center Adds Clinical Laboratory and Patient Engagement Expertise to Governing Committee – Business Wire 4 years agoAbnormal temperatures linked to climate change cause over 740,000 deaths annually in India
Monday, May 12, 2025
Primary Menu
  • Categories
    • Real World Research (RWR)
    • RWD Sources
    • Movers and Shakers
    • RWE – Real World Evidence
    • Health Tech
    • Medical Devices
    • RWR & COVID 19
    • Regulatory
    • Oncology
    • Mental Health
    • Schrödinger’s Donkey
    • Decentralised Trials
    • Recently Released
  • Editorials
  • RWR
  • Newsfeed
  • FAQ
  • ABOUT
    • About RWR News
    • About the Authors
    • RWR News Editorial Policy
  • RESOURCES
    • Phoenix RWR Consulting
    • RedBird Reg Intel Tools
    • RWR Study Master File

Tag: Pharmacology

  • Home
  • Pharmacology
Category:
  • Real World Research (RWR)
  • Recently Released
  • RWE - Real World Evidence

Anaphylaxis Risk Compared for Monoclonal Antibodies Used for Severe Asthma – Medical Bag

Real-World Research shows comparative risk for mAbs used in severe asthma patients CONTEXT:  According to the findings of a real-world research study published in Clinical and Translational Allergy, patients receiving Continue Reading

Posted On : July 3, 2021 Published By : Mark Lorkowski
Category:
  • Real World Research (RWR)
  • Recently Released
  • RWE - Real World Evidence

On the Real-World Safety of Tofacitinib in Rheumatoid Arthritis – MedPage Today

CONTEXT: Publication of an RWR study in rheumatoid arthritis showing equivalent safety profile between a biologic DMARD and an oral Janus kinase inhibitor.    IMPACT:  Low READ TIME:  2 mins Continue Reading

Posted On : April 20, 2021 Published By : stuart.mccully
Category:
  • Real World Research (RWR)
  • Recently Released

Real World Research example in rare disease use case

CONTEXT: Real world research showing value in rare disease research where RCTs cannot generate the statistical power traditionally needed with so few available patients. New methods to interpret the RWD Continue Reading

Posted On : February 16, 2021 Published By : Mark Lorkowski
Category:
  • Recently Released
  • RWE - Real World Evidence

ADA: Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugar – FiercePharma

IMPACT: Taking insulin and a GLP-1 agonist significantly increases the ability of achievement stable blood sugar levels READ TIME: 2 mins * 1. “Sanofi’s Soliqua combines an insulin with a Continue Reading

Posted On : February 8, 2021 Published By : Mark Lorkowski
Category:
  • Recently Released
  • RWE - Real World Evidence

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program – MD Linx

EXPERT NOTES: CONTEXT:  Peer Reviewed Data, RWE of Effectiveness of Cabozantinib IMPACT:  In the largest real-world study to date, cabozantinib was effective in unselected, heavily pretreated patients with mRCC. Initiation Continue Reading

Posted On : January 29, 2021 Published By : stuart.mccully
Category:
  • Pharmacovigilance (post-approval)
  • Recently Released

News: Human medicines: highlights of 2020

Quick Notes: *Within the report the “conditional marketing authorisations” and “monitoring in real-life” are the “go to” section to see what the post-authorisation obligations were and what the EMA is Continue Reading

Posted On : January 29, 2021 Published By : stuart.mccully

XKCD Mental Break

Coffee Break Cartoon XKCD

We don’t spam! Read more in our privacy policy

Check your inbox or spam folder to confirm your signup and download

Copyright RedBird 2021
Theme: Royal Magazine by ThemeinWP
  • Cookie Policy (EU)
  • Privacy Statement (EU)
  • Impressum
  • Cookie Policy (UK)
  • Privacy Statement (UK)
  • Cookie Policy (US)
  • Cookie Policy (CA)
  • Privacy Statement (CA)
  • Disclaimer
  • Privacy Statement (US)
Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}